Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTISTRY-1: Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1
NCT05502341Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of bictegravir, lenacapavir in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Aug 2022; status: active, not recruiting.
02
Drugs
bictegravirlenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05502341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502341.